| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_572ab08e5c5598e0ba015be1d722298c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-51 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-4823
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6939
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate |
2016-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29dc5211238db27334383bc0f74b8cf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cca0c01948a5d6ad9f08a12705e3ad0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e676435e88097ff627c1c435021bb009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf3e9cad0c87682e90ef57a52adc9c40 |
| publicationDate |
2016-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016310516-A1 |
| titleOfInvention |
Conjugate of ginsenoside compound k and glycol chitosan and an anti-tumor use thereof |
| abstract |
The present invention relates to a conjugate of ginsenoside compound K and glycol chitosan, a method for preparing the conjugate, and a pharmaceutical composition for treating cancer including the conjugate in a pharmaceutically acceptable carrier. n The conjugate of ginsenoside compound K and glycol chitosan of the present invention has cancer cell-specific anticancer activity because of increased water solubility relative to ginsenoside compound K, formation of nanosized self-aggregates in an aqueous solution, stability at neutral pH and release of the ginsenoside compound K at acidic pH due to pH sensitivity, thus having excellent effects as a composition for treating cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116172944-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110366419-A |
| priorityDate |
2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |